Cargando…
Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?
Autores principales: | Gérard, Alexandre O., Laurain, Audrey, Favre, Guillaume, Drici, Milou-Daniel, Esnault, Vincent L.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862288/ https://www.ncbi.nlm.nih.gov/pubmed/35973076 http://dx.doi.org/10.2337/dc22-0921 |
Ejemplares similares
-
New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review
por: Gérard, Alexandre O., et al.
Publicado: (2022) -
Drug-Induced Tubulointerstitial Nephritis: Insights From the World Health Organization Safety Database
por: Gérard, Alexandre O., et al.
Publicado: (2022) -
Extracellular fluid volume: A suitable indexation variable to assess impact of bariatric surgery on glomerular filtration rate in patients with chronic kidney disease
por: Grangeon-Chapon, Caroline, et al.
Publicado: (2021) -
Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes
por: Hamblin, Peter S., et al.
Publicado: (2021) -
Risk factors associated with immune checkpoint inhibitor–induced acute kidney injury compared with other immune-related adverse events: a case–control study
por: Gérard, Alexandre O, et al.
Publicado: (2022)